1 INDICATIONS AND USAGE
Tigecycline for injection is a tetracycline-class antibacterial indicated in patients 18 years of age and older for:
Complicated skin and skin structure infections (
1.1)
Complicated intra-abdominal infections (
1.2)
Community-acquired bacterial pneumonia (
1.3)
Limitations of Use: Tigecycline for injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia (
1.4).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs, Tigecycline for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.
1.1 Complicated Skin and Skin Structure Infections
Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of
Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates),
Staphylococcus aureus (methicillin-susceptible and -resistant isolates),
Streptococcus agalactiae, Streptococcus anginosus grp. (includes
S. anginosus, S. intermedius, and
S. constellatus),
Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and
Bacteroides fragilis.
1.2 Complicated Intra-abdominal Infections
Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections caused by susceptible isolates of
Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates),
Staphylococcus aureus (methicillin-susceptible and -resistant isolates),
Streptococcus anginosus grp. (includes
S. anginosus, S. intermedius, and
S. constellatus),
Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and
Peptostreptococcus micros.
1.3 Community-Acquired Bacterial Pneumonia
Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of community-acquired bacterial pneumonia caused by susceptible isolates of
Streptococcus pneumoniae (penicillin-susceptible isolates), including cases with concurrent bacteremia,
Haemophilus influenzae , and
Legionella pneumophila.
1.4 Limitations of Use
Tigecycline for injection is not indicated for the treatment of diabetic foot infections. A clinical trial failed to demonstrate non-inferiority of tigecycline for injection for treatment of diabetic foot infections.
Tigecycline for injection is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia. In a comparative clinical trial, greater mortality and decreased efficacy were reported in tigecycline for injection -treated patients
[see
Warnings and Precautions (5.2)].
1.5 Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs, tigecycline for injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to tigecycline. Tigecycline for injection may be initiated as empiric monotherapy before results of these tests are known.